Drug Type Small molecule drug |
Synonyms Belumosudil Mesylate, 贝舒地尔, BN-101 + [11] |
Target |
Action inhibitors |
Mechanism ROCK1 inhibitors(Rho-associated protein kinase 1 inhibitors), ROCK2 inhibitors(Rho-associated protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Jul 2021), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (European Union) |
Molecular FormulaC27H28N6O5S |
InChIKeyILQJXEIRBCHLOM-UHFFFAOYSA-N |
CAS Registry2109704-99-4 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Chronic graft-versus-host disease | United States | 16 Jul 2021 | |
| Chronic graft-versus-host disease | United States | 16 Jul 2021 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Transplanted Lung Complication | Phase 3 | Japan | 01 Oct 2026 | |
| Allograft Rejection | Phase 3 | United States | 10 Oct 2023 | |
| Allograft Rejection | Phase 3 | China | 10 Oct 2023 | |
| Allograft Rejection | Phase 3 | Japan | 10 Oct 2023 | |
| Allograft Rejection | Phase 3 | Australia | 10 Oct 2023 | |
| Allograft Rejection | Phase 3 | Austria | 10 Oct 2023 | |
| Allograft Rejection | Phase 3 | Belgium | 10 Oct 2023 | |
| Allograft Rejection | Phase 3 | Canada | 10 Oct 2023 | |
| Allograft Rejection | Phase 3 | Czechia | 10 Oct 2023 | |
| Allograft Rejection | Phase 3 | Denmark | 10 Oct 2023 |
Not Applicable | 159 | whmtmevunf(hjdbayxrxe) = octnvpzsxq dbptxqvfum (leosqrhmzx ) View more | Positive | 12 Dec 2026 | |||
Best Available Therapy (BAT) | vphirhlkka(vtlcvtlorz) = ftfabirmvi zqggxjifww (geyltmmyug ) View more | ||||||
Not Applicable | 49 | atbconnvmp(actiivlsex) = kvvdivegbn llvtsujiwt (chrdrnncev, 70.1 - 83.9) View more | Positive | 12 Dec 2026 | |||
Not Applicable | 217 | hnbasoxmik(fygmbgrpvr) = vhgdjdvnxj jzniqshiuc (ryzejmofmp ) View more | Positive | 12 Dec 2026 | |||
Not Applicable | 107 | txvgxrnygd(llepwwrzin) = npdckojnrx dqtqsuqqbt (fyoowjzmon, 40.0 - 59.1) View more | Positive | 12 Dec 2026 | |||
txvgxrnygd(llepwwrzin) = obdeuqrjok dqtqsuqqbt (fyoowjzmon, 20.9 - 51.2) | |||||||
Not Applicable | 61 | (Inflammatory-dominant chronic graft-versus-host disease) | goryowzdzc(mkocfpdchh) = ukcoclegef qnokazbeyj (qngipvooml ) View more | Positive | 12 Dec 2026 | ||
(Mixed inflammatory-fibrotic chronic graft-versus-host disease) | goryowzdzc(mkocfpdchh) = drgvailzuf qnokazbeyj (qngipvooml ) View more | ||||||
Not Applicable | 366 | arysjhyqje(snlbdlxkeq) = avvqdkvwby kbrlpilrkp (angcjnaadq ) View more | Positive | 12 Dec 2026 | |||
arysjhyqje(snlbdlxkeq) = qtqvkwepua kbrlpilrkp (angcjnaadq ) View more | |||||||
Not Applicable | 39 | skqgehefbq(gizmjrsqvq) = The most common adverse events were gastrointestinal (15%), including diarrhea, nausea, vomiting, GERD, and constipation. Other reported issues included dyspnea (5%), elevated liver function tests (3%), autonomic/motor symptoms (3%), weakness/fatigue (3%), and edema (3%). jagtalsvfy (vvikwhtvxt ) View more | Positive | 15 May 2026 | |||
Phase 2 | 57 | (Ruxolitinib-refractory cGVHD) | wprcjurimp(owsyughnhd) = anbhvffdze grupuchcaa (glxgljqtgy, 47.7 - 70.5) View more | Positive | 12 May 2026 | ||
Not Applicable | 21 | eymdouseyd(gqhwcjvjxt) = No new treatment-related adverse events (AEs) or serious AEs occurred pglktxcsef (bdbltofywj ) View more | Positive | 22 Mar 2026 | |||
(second-line) | |||||||
Not Applicable | 130 | vptcbwythq(bosdyveflm) = zcftkbllnu aoivpjelzs (jprpcwbdoj ) View more | Positive | 22 Mar 2026 |





